Cellax™
Targeted Cancer Stromal Delivery
Unmet Medical Needs
The tumor microenvironment (TME) can be hostile to our body’s immune system, making it challenging for immune cells to identify and fight cancer cells. The TME can accomplish this in several ways, including the secretion of certain molecules that hinder immune cell function, or by physically blocking immune cells from entering the tumor through the dense extracellular matrix. This immunosuppressive environment can make it difficult to combat cancer, and new therapies are needed to overcome these challenges.
Our Solutions
Introducing Cellax™, a polysaccharide-drug conjugate platform technology that delivers non-selective, water-insoluble, and short-acting drugs to tumors. By prolonging drug exposure and increasing drug delivery to the TME, Cellax™ can help shrink tumors and prolong survival. Unlike checkpoint inhibitors and CAR-T cell therapy, Cellax™ can overcome the challenge of “immune-cold tumors” by depleting cancer-associated fibroblasts (CAFs), which can otherwise suppress the immune system. As a result, Cellax™ has the potential as a standalone or complementary therapy to enhance solid tumor treatment efficacy.
- Bone penetration
- Sustained drug release (5% per day)
- Reprogram TME through stromal depletion
- Enhance tumor vessel perfusion and drug delivery
- No neutropenia or suppression of host immune system
